New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
11:01 EDTNVS, ESI, AFFY, KBR, NRFHigh option volume stocks: NVS ESI AFFY KBR NRF
News For NVS;ESI;AFFY;KBR;NRF From The Last 14 Days
Check below for free stories on NVS;ESI;AFFY;KBR;NRF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
08:10 EDTKBRKBR awarded EPC contract for new HDPE facility in La Porte, Texas
KBR announced it has been awarded a contract from Gemini HDPE, a manufacturing joint venture between INEOS Olefins & Polymers USA and Sasol, to provide engineering, procurement, and construction, or EPC, services for a new high-density polyethylene, or HDPE, facility to be located at INEOS's Battleground Manufacturing Complex in La Porte, Texas. The new facility is designed to produce 470 kilotons per annum of bimodal HDPE using Innovene S process technology licensed from INEOS Technologies. The new, single-train facility will include new polymerization, pelletization, and railcar load-out facilities, plus upgrades to existing utilities and infrastructure.
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 14, 2014
17:00 EDTNRFGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
August 11, 2014
08:10 EDTNRFNorthstar Realty added to Top Picks List at FBR Capital
Subscribe for More Information
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
August 8, 2014
10:36 EDTESIOptions with increasing implied volatility
Subscribe for More Information
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use